Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Sells 3,982 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 3,982 shares of the firm's stock in a transaction that occurred on Thursday, July 10th. The stock was sold at an average price of $12.00, for a total value of $47,784.00. Following the transaction, the chief operating officer owned 744,936 shares in the company, valued at approximately $8,939,232. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Scott Lish also recently made the following trade(s):

• On Friday, June 13th, Scott Lish sold 22,727 shares of Alphatec stock. The stock was sold at an average price of $11.07, for a total value of $251,587.89.
• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The stock was sold at an average price of $13.00, for a total value of $719,875.00.
• On Monday, May 5th, Scott Lish sold 12,000 shares of Alphatec stock. The stock was sold at an average price of $12.12, for a total value of $145,440.00.

Alphatec Price Performance

ATEC stock traded up $0.06 on Thursday, reaching $10.69. 339,698 shares of the company traded hands, compared to its average volume of 2,065,634. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $13.14. The company has a market cap of $1.56 billion, a P/E ratio of -9.30 and a beta of 1.05. The firm has a fifty day simple moving average of $11.78 and a 200-day simple moving average of $11.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). The company had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative net margin of 25.77% and a negative return on equity of 1,657.19%. The firm's quarterly revenue was up 22.2% on a year-over-year basis. During the same period last year, the business earned ($0.34) EPS. On average, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Institutional Trading of Alphatec

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp grew its holdings in shares of Alphatec by 119.3% in the fourth quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company's stock worth $6,079,000 after acquiring an additional 360,258 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Alphatec by 2.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 846,224 shares of the medical technology company's stock worth $7,768,000 after acquiring an additional 23,002 shares during the period. Atria Investments Inc grew its holdings in shares of Alphatec by 20.3% in the fourth quarter. Atria Investments Inc now owns 23,585 shares of the medical technology company's stock worth $217,000 after acquiring an additional 3,976 shares during the period. M&T Bank Corp bought a new stake in shares of Alphatec in the fourth quarter worth $170,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Alphatec in the fourth quarter worth $358,000. Institutional investors own 66.35% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ATEC shares. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Piper Sandler restated an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 target price for the company in a research note on Monday, June 16th. Finally, Needham & Company LLC restated a "buy" rating and issued a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Alphatec has a consensus rating of "Moderate Buy" and an average target price of $18.13.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.